Meghan H Pearl

Summary

Affiliation: University of California
Country: USA

Publications

  1. Pearl M, Reed E. Angiotensin II type I receptor antibodies in pediatric solid organ transplant. Hum Immunol. 2019;: pubmed publisher
    ..The mechanisms by which autoimmunity is provoked and mediates organ dysfunction in childhood and effective treatment options require further research. ..
  2. Pearl M, Leuchter R, Reed E, Zhang Q, Ettenger R, Tsai E. Accelerated rejection, thrombosis, and graft failure with angiotensin II type 1 receptor antibodies. Pediatr Nephrol. 2015;30:1371-4 pubmed publisher
    ..The role of treatment with anti-coagulation and novel immunomodulatory agents such as tocilizumab and bortezomib require further investigation. ..
  3. Pearl M, Nayak A, Ettenger R, Puliyanda D, Palma Diaz M, Zhang Q, et al. Bortezomib may stabilize pediatric renal transplant recipients with antibody-mediated rejection. Pediatr Nephrol. 2016;31:1341-8 pubmed publisher
    ..Reduction in HLA DSAs was more effective for class I than class II. Bortezomib appears safe and may correlate with stabilization of eGFR in pediatric kidney transplant patients with refractory C4d + AMR. ..
  4. Pearl M, Zhang Q, Palma Diaz M, Grotts J, Rossetti M, Elashoff D, et al. Angiotensin II Type 1 receptor antibodies are associated with inflammatory cytokines and poor clinical outcomes in pediatric kidney transplantation. Kidney Int. 2018;93:260-269 pubmed publisher
    ..AT1R antibody and inflammatory cytokines may identify those at risk for renal vascular inflammation and lead to early biopsy and intervention in pediatric kidney transplantation. ..